Oral oncology最新文献

{"title":"Long-Term outcomes of induction chemotherapy–guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials","authors":"J.T. Lovett ,&nbsp;M.T. Wotman ,&nbsp;W.H. Westra ,&nbsp;S. Ahn ,&nbsp;V. Gupta ,&nbsp;R.L. Bakst ,&nbsp;Scott Roof ,&nbsp;B.A. Miles ,&nbsp;E Genden ,&nbsp;K. Misiukiewicz ,&nbsp;L. Worona ,&nbsp;E. Ramos ,&nbsp;J. Botzler ,&nbsp;T. Chen ,&nbsp;M. Posner","doi":"10.1016/j.oraloncology.2026.107858","DOIUrl":"10.1016/j.oraloncology.2026.107858","url":null,"abstract":"<div><h3>Importance</h3><div>The rising incidence of HPV-positive oropharynx cancer (HPV-OPC) underscores the need for treatment strategies that maintain disease control while minimizing long-term toxicity. This study reports the long-term follow-up of de-escalation in poor prognosis HPV-OPC, providing critical data for future studies.</div></div><div><h3>Objective</h3><div>To evaluate long-term outcomes in patients with locally advanced HPV-OPC treated with induction chemotherapy (IC) followed by reduced-dose chemoradiation (rdCRT). We hypothesized that de-escalated radiation therapy after IC would be non-inferior to standard-dose CRT (sdCRT).</div><div>Design: Two sequential clinical trials; Quarterback (QB) 1: phase III randomized control trial, QB 2: phase II non-randomized trial; patient accrual conducted between December 2012 and February 2022; final data cutoff April 2025. Median follow-up (IQR): 88.5 (64.6–118.2) months.</div><div>Setting: Single-institution academic center.</div><div>Participants: 62 patients with HPV-OPC were screened. 47 patients received rdCRT after IC and were included in the primary analysis. Key eligibility: smoking history ≤20 pack-years, no active smoking, no distant metastases, molecularly confirmed HPV status.</div><div>Interventions: Three cycles of induction TPF (docetaxel, cisplatin, 5-fluorouracil) followed by rdCRT (5600 cGy) with weekly carboplatin in clinical responders; non-responders in both QB trials and responders in the control arm of QB1 received sdCRT (7000 cGy).</div><div>Main Outcomes and Measures: Primary endpoints: 3-year locoregional relapse-free survival (LRRFS) and 3-year progression-free survival (PFS). Secondary: overall survival (OS). Tertiary: disease-specific survival.</div></div><div><h3>Results</h3><div>Among 47 patients treated with rdCRT after IC, the 3-year and 5-year LRRFS were 89.3% and 86.6%. PFS was 87.2% and 84.6% at 3 and 5 years. OS was 91.5% and 89.1% at 3 and 5 years. Six patients (13%) experienced locoregional failure, and two (4%) developed distant metastases. 7/8 treatment failures (87.5%) occurred in patients with extracapsular extension.</div></div><div><h3>Conclusions and Relevance</h3><div>rdCRT following IC yields durable disease control in poor prognosis HPV-OPC, with outcomes comparable to historical benchmarks. Extended follow-up supports the safety and efficacy of this de-escalation strategy, even in patients with aggressive disease characteristics, but also underscores the need for careful patient selection, particularly in those with extracapsular extension.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107858"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146019168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview","authors":"Sachender Pal Singh ,&nbsp;Supriya Prasad ,&nbsp;Purnima Maggi Dean ,&nbsp;Asha Lata Kujur ,&nbsp;Gagan Jaiswal","doi":"10.1016/j.oraloncology.2026.107862","DOIUrl":"10.1016/j.oraloncology.2026.107862","url":null,"abstract":"<div><h3>Objective</h3><div>Extranodal extension (ENE) of cervical lymph node metastases is a key prognostic factor in head and neck squamous cell carcinoma (HNSCC). This systematic review and meta-analysis evaluated the survival impact of ENE in HNSCC and identified global research trends relevant to this research field through a complementary bibliometric analysis.</div></div><div><h3>Materials and methods</h3><div>ScienceDirect, PubMed, and Scopus were systematically searched during 2000–2025. A systematic review and a meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. A Scopus-based bibliometric analysis was conducted using the Biblioshiny package of R to identify and map the publication trends, influential authors, and major institutional contributions between 2010 and 2025.</div></div><div><h3>Results</h3><div>Of the 839 retrieved records, 711 studies were screened, and 16 studies comprising approximately 3900 patients met all inclusion criteria. The bibliometric analysis of 120 Scopus-indexed publications demonstrated a marked increase in ENE-related research from 2015 onward, driven primarily by institutions in Australia, Taiwan, and South Korea. Keyword mapping indicated expanding intersections of ENE research with radiomics, prognostic modelling, and refinement of staging systems. Meta-analysis confirmed a significant association between ENE and adverse survival outcomes. Subgroup analyses showed consistently poor prognostic implications across both pathologic and radiologic ENE assessments.</div></div><div><h3>Conclusion</h3><div>ENE in cervical lymph node metastases is an independent and strong predictor of adverse survival in HNSCC. The increasing global attention to ENE highlights its crucial role in multidisciplinary oncologic management. Therefore, standardized pathological and imaging-based assessment of ENE is essential for developing superior prognostic models and optimizing future treatment planning strategies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107862"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical lymph node metastasis in oral squamous cell carcinoma: From metastatic patterns and risk factors to the development and validation of a predictive model","authors":"Xiao-Hu Wang ,&nbsp;Lei-Ming Cao ,&nbsp;Zhao-Qi Zhu ,&nbsp;Yao Xiao ,&nbsp;Han-Yue Luo ,&nbsp;Guang-Rui Wang ,&nbsp;Kan Zhou ,&nbsp;Yi-Fu Yu ,&nbsp;Jun Jia ,&nbsp;Bing Liu ,&nbsp;Lin-Lin Bu","doi":"10.1016/j.oraloncology.2026.107860","DOIUrl":"10.1016/j.oraloncology.2026.107860","url":null,"abstract":"<div><div>Cervical lymph node metastasis (CLNM) is the most critical prognostic factor in oral squamous cell carcinoma (OSCC). To facilitate individualized risk assessment, this study aimed to develop and internally validate a novel prediction model. We retrospectively analyzed 3723 patients with OSCC from a single center (2012–2023), with 2792 eligible patients randomly allocated to a training (n = 1954) and a validation set (n = 838). A rigorous variable selection process was employed, where predictors significant in univariable analysis were entered into a multivariable logistic regression model that utilized a stepwise forward and backward elimination procedure to identify the final set of predictors. Six factors were ultimately incorporated into the nomogram: clinical T stage, clinical N stage, histological grade, perineural invasion, time from onset to treatment, and alcohol consumption. The model demonstrated good discrimination in both training (AUC = 0.780) and validation (AUC = 0.744), excellent calibration, and clinical utility. In conclusion, this internally validated nomogram accurately predicts CLNM risk and can aid in tailoring neck management, pending external validation.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107860"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146019157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery”","authors":"Ling Zhang","doi":"10.1016/j.oraloncology.2026.107881","DOIUrl":"10.1016/j.oraloncology.2026.107881","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107881"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour microenvironment diversity of HNSCC and the molecular landscape of recurrent disease","authors":"Katelyn Steele ,&nbsp;Catherine Barnett ,&nbsp;Rahul Ladwa ,&nbsp;Meg L Donovan ,&nbsp;Clara Lawler ,&nbsp;Arutha Kulasinghe","doi":"10.1016/j.oraloncology.2026.107864","DOIUrl":"10.1016/j.oraloncology.2026.107864","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) represents a biologically diverse group of malignancies within the upper aerodigestive tract and oral cavity and remains a significant cause of global morbidity and mortality. Increasing evidence highlights that the tumour microenvironment (TME) plays a central role in disease progression and therapeutic response. Distinct immune and stromal profiles have been observed between HPV positive (HPV+) and HPV negative (HPV-) HNSCC, underpinning their differing natural history and responses to immunotherapy. Despite advances, only 15–20% of patients with recurrent or metastatic HNSCC (RMHNSCC) respond to immunotherapy, with no difference in response being seen between HPV+ and HPV- disease. This may reflect the complexity and heterogeneity of the TME. This review explores how emerging spatial omics technologies, combining molecular, and spatial context, are reshaping our understanding of the HNSCC microenvironment, with emphasis on recurrent and/or metastatic disease. By delineating the spatial organisation of immune, stromal, and metabolic features, these approaches provide new insights into mechanisms of treatment resistance, prognostic biomarkers, and therapeutic vulnerabilities. Understanding spatial TME dynamics across HPV-related subtypes may ultimately guide more precise and effective treatment strategies for HNSCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107864"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first report of contralateral parapharyngeal space metastasis of papillary thyroid carcinoma: report of a case","authors":"Nan Wang ,&nbsp;Haotian Gao ,&nbsp;Shuai-xia Yu ,&nbsp;Jiangang Fan ,&nbsp;Bin Li ,&nbsp;Xiaolong Zhao","doi":"10.1016/j.oraloncology.2026.107865","DOIUrl":"10.1016/j.oraloncology.2026.107865","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107865"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term swallowing outcomes following transoral robotic surgery for oropharyngeal cancer – Five years and beyond","authors":"Bartosz P. Wojtera ,&nbsp;Avinash Beharry ,&nbsp;Victoria Salati ,&nbsp;Karma Lambercy ,&nbsp;Nina Wahler ,&nbsp;Edouard Romano ,&nbsp;Wojciech Golusinski ,&nbsp;Christian Simon","doi":"10.1016/j.oraloncology.2026.107876","DOIUrl":"10.1016/j.oraloncology.2026.107876","url":null,"abstract":"<div><div>Objective: Transoral robotic surgery (TORS), either used alone or combined with radiotherapy, is a common treatment for operable T-stage oropharyngeal squamous cell carcinoma (OPSCC). Due to high survival rates, maintaining quality of life—especially swallowing function—is an important long-term consideration. This study aimed to assess swallowing outcomes five years and beyond following TORS in patients with primary OPSCC.</div><div>Methods: “Functional outcome swallowing scale” (FOSS) was used to retrospectively assess long-term dysphagia in 47 OPSCC patients, with a median follow-up of 6.8 years. All patients had a minimum follow-up of five years.</div><div>Results: The FOSS scores remained stable at five years compared to 1–4 years post-TORS (all p &gt; 0.99). Furthermore, there were no significant differences in FOSS from 1 to 10 years post-TORS compared to preoperative score. Adjuvant therapy was a univariate predictor of worse swallowing outcomes (OR: 17.46, 95% CrI: 2.94–121.51); however, this effect was limited to the short-term postoperative period (≤ 2 years after TORS). In contrast, subsequent major surgery after TORS and treatment of more advanced tumors (pT2–pT3 vs. pTis–pT1) were associated with persistently worse swallowing outcomes, including long-term follow-up (OR: 23.81, 95% CrI: 4.48–142.59; OR: 15.03, 95% CrI: 3.06–81.45, respectively).</div><div>Conclusions: TORS offers excellent and stable long-term swallowing outcomes when used as a single-modality treatment for OPSCC. While outcomes remain satisfactory with additional therapies, swallowing results are influenced by tumor stage, adjuvant treatment, and further major surgery.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107876"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy and betel nut-associated oral cavity carcinoma: challenges and opportunities","authors":"William J. Moss ,&nbsp;Jonathan West ,&nbsp;Peter Brett ,&nbsp;Daniel Kwon","doi":"10.1016/j.oraloncology.2026.107873","DOIUrl":"10.1016/j.oraloncology.2026.107873","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107873"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare laryngeal tumors: A retrospective bicentric study on 74 patients and systematic review","authors":"Francesco Chu ,&nbsp;Pietro Benzi ,&nbsp;Marta Tagliabue ,&nbsp;Chiara Mossinelli ,&nbsp;Stefano Filippo Zorzi ,&nbsp;Sara Gandini ,&nbsp;Marco Romelli ,&nbsp;Marta Filauro ,&nbsp;Andrea Iandelli ,&nbsp;Filippo Marchi ,&nbsp;Giorgio Peretti ,&nbsp;Mohssen Ansarin","doi":"10.1016/j.oraloncology.2026.107852","DOIUrl":"10.1016/j.oraloncology.2026.107852","url":null,"abstract":"<div><h3>Introduction</h3><div>Head and neck cancers are the seventh most common malignancy worldwide, with laryngeal cancer (LC) the most prevalent subtype. Although squamous cell carcinoma (SCC) represents 85–90% of LC, rare non-SCC tumors—including laryngeal sarcomas (LS), neuroendocrine carcinomas (LNC), malignant salivary gland tumors (LMSGT), and mucosal melanomas (LMM)—are uncommon but clinically challenging. We combined a bicentric retrospective cohort with a systematic literature review to provide an integrated assessment of these entities.</div></div><div><h3>Methods</h3><div>Patients with non-SCC malignant laryngeal tumors treated with curative intent at two Italian tertiary centers were retrospectively analyzed. Tumors were classified as LS, LNC, LMSGT, or LMM. Primary endpoints were overall survival (OS), disease specific survival (DSS) and recurrence-free survival (RFS). A systematic review contextualized institutional outcomes.</div></div><div><h3>Results</h3><div>74 patients were included: 34 LS, 25 LNC, 13 LMSGT, and 2 LMM. Surgery was the primary treatment in 98.6 % of cases. LS and LMSGT demonstrated favorable survival, whereas LNC showed poor outcomes (median OS, 2.89 years) and the highest recurrence rate (72 %). Radical tumor excision achieved effective loco-regional control across histologies. LMM prognosis was dismal, with recurrence in both cases. The literature review revealed marked heterogeneity and wide survival ranges, reflecting rarity and biological diversity.</div></div><div><h3>Conclusion</h3><div>Rare non-SCC laryngeal tumors comprise heterogeneous and often aggressive diseases with variable prognoses. Despite the absence of standardized management, radical surgery provides effective loco-regional control. Integrating bicentric clinical experience with published evidence highlights the need for multicenter collaboration to optimize treatment strategies and improve outcomes in this rare oncologic setting worldwide today.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"174 ","pages":"Article 107852"},"PeriodicalIF":3.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research","authors":"Mahad Chaudhry ,&nbsp;Annes Elfar ,&nbsp;Kaylyn Rowsey ,&nbsp;Andrew Neel ,&nbsp;Adam Khan ,&nbsp;Ty Lutze ,&nbsp;David Wenger ,&nbsp;Matt Vassar","doi":"10.1016/j.oraloncology.2025.107840","DOIUrl":"10.1016/j.oraloncology.2025.107840","url":null,"abstract":"<div><h3>Introduction</h3><div>Head and Neck Squamous Cell Carcinoma (HNSCC) is a debilitating malignancy that requires a multimodal approach in treatment, which is associated with a considerable burden of adverse events (AE). Since the 2007 FDA Amendments Act (FDAAA 801) mandates comprehensive AE reporting on ClinicalTrials.gov, the consistency of these data with corresponding peer‑reviewed publications remains unclear. This study examines the consistency of AE reporting between ClinicalTrials.gov and peer-reviewed publications for HNSCC randomized clinical trials (RCTs) conducted post-FDAAA implementation.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively analyzed AE reporting on Phase II-IV HNSCC RCTs registered on clinicaltrials.gov between September 27, 2009, and January 15, 2025. Data was extracted on participant counts and total events for serious adverse events (SAEs), other adverse events (OAEs), all-cause mortality (ACM), and treatment discontinuation. Discrepancies were defined as any mismatch in counts or reporting. Chi-square and Mann-Whitney U tests assessed differences in reporting frequencies and publication delays between trial and publication data.</div></div><div><h3>Results</h3><div>Overall, 60 trials met inclusion criteria. All 60/60 (100 %) trials reported participants affected by SAEs versus 43/60 (71.7 %) publications (p &lt; 0.05), of which 33/43 (76.7 %) showed discrepant counts. Likewise, 60/60 (100 %) trials versus 22/60 (36.7 %) publications reported participants affected by OAEs (p &lt; 0.05), with 18/22 (81.8 %) mismatches. Among 24/24 (100 %) trials completed post‑2017, ACM was reported on ClinicalTrials.gov versus 15/24 (62.5 %) publications, and 22/24 (91.7 %) of those pairs differed. Participant discontinuations due to AEs appeared in 17/60 (28.3 %) registries versus 39/60 (65.0 %) publications (p &lt; 0.05); of the 15/17 (88.2 %) with both sources reporting, 9/15 (60.0 %) had discordant counts.</div></div><div><h3>Conclusion</h3><div>Substantial inconsistencies in AE, mortality, and discontinuation reporting persist between ClinicalTrials.gov and peer‑reviewed publications of HNSCC RCTs. To uphold transparency and patient safety, enhanced technical safeguards on registry platforms and stricter journal policies, such as mandatory discrepancy checklists, are urgently needed.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107840"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}